Trust Company.CitigroupCowen and CompanyStifelNeedham & Company, 2014Table of ContentsTABLE OF CONTENTSPageSummary1The Offering8Summary Financial Data9Risk Factors11Cautionary Note Regarding Forward-Looking Statements44Use of Proceeds46Market Price of Our Common Stock47Dividend Policy48Capitalization49Dilution50Business51Management89Executive and Director Compensation97Certain Relationships and Related Party Transactions107Principal Stockholders109Description of Capital Stock114Shares Eligible for Future Sale119Material United States Federal Income and Estate Tax Considerations for Non-U.S. Holders122Underwriting127Legal Matters133Experts133Where You Can Find More Information133Incorporation of Documents By Reference133We are responsible for the information contained in this prospectus and in any free-writing prospectus we prepare or authorize.
these factors will significantly increase our likelihood of success in efficiently discovering T cell-based vaccines against diseases associated with unmet needs.GEN-003: A Therapeutic Vaccine Candidate for HSV-2HSV-2 is a sexually transmitted disease affecting approximately 16% of the United States population between the ages of 14 to 49, and
We therefore believe GEN-003 can be an important treatment option for people infected with HSV-2.GEN-004: A Prophylactic Vaccine Candidate for PneumococcusOur second program derived from ATLAS is GEN-004, a T cell vaccine that we are developing to protect against all strains of the
This collaboration extends the use of our proprietary ATLAS platform for the potential rapid discovery of T cell antigens to cancer immunotherapy approaches.Our Product Candidate PipelineThe following table describes our current development programs:Vaccine CandidateProgramStage ofDevelopmentNext MilestoneAnticipatedTimelineGEN-003HSV-2 TherapeuticPhase 2Complete Phase 2 dose optimizationMid-2015GEN-004Pneumococcus ProphylaxisPhase 2aComplete Phase 2aMid-2015GEN-001Chlamydia ProphylaxisPre-clinicalFile IND2017GEN-002HSV-2 ProphylaxisPre-clinicalFile IND2017GEN-005Malaria ProphylaxisResearchInitiate pre-clinical studiesSecond half of 20154Table of ContentsOur TeamOur management and scientific teams possess considerable experience in vaccine and anti-infective research, manufacturing, clinical
a novel approach for vaccines and medical treatments and therefore could produce unexpected adverse clinical outcomes or result in delays in our obtaining regulatory approval.•If our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities we may
for us to predict the requirements the United States Food and Drug Administration, or FDA, or other regulatory agencies may impose to demonstrate the safety of the product candidate.•We expect to rely on third parties to conduct the majority of our product manufacturing and clinical development of our
If they fail to meet deadlines or perform in an unsatisfactory manner, our business could be harmed.•Our future commercial success depends upon attaining significant market acceptance of our product candidates, if approved,
product candidate that we are developing to prevent infections caused by all strains of pneumococcus;•initiate additional non-clinical, clinical or other studies for our other product candidates;•manufacture material for clinical trials and for commercial sale;•seek regulatory approvals for our product candidates that successfully complete clinical trials;11Table of Contents•establish a sales, marketing and distribution infrastructure to commercialize any products for which we may obtain
product candidates, including our planned Phase 2a clinical trial of GEN-004;•the number and development requirements of other product candidates that we pursue;•the timing of, and the costs involved in, obtaining regulatory approvals for our product candidates if clinical trials are
candidates or delay, limit, reduce or terminate our establishment of sales and marketing capabilities or other activities that may be necessary to commercialize our product candidates.13Table of ContentsRaising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to relinquish rights to our technologies or product
approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy.If we do not obtain regulatory approval for our current and future product candidates, our business will be adversely affected.Our product candidates are subject to extensive governmental regulations relating to, among other things, research, clinical trials,
for our product candidates in the United States or in countries outside of the United States.We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive
obtain regulatory approval and will not be able to commercialize our product candidates.Our product candidates, including GEN-003 and GEN-004, are based on T cell activation, which is a novel approach for vaccines, immunotherapies and medical treatments.
addition, such a change in methodology may cause us to need to restate or correct information that we had previously disclosed regarding the statistical significance of our clinical trial results.Risks Related to Our Reliance on Third PartiesWe rely on third parties to conduct non-clinical studies and clinical trials for our product candidates, and if they do not properly and successfully perform their
of these events could lead to clinical trial delays or failure to obtain regulatory approval, or affect our ability to successfully commercialize future products.
a result, any delay or interruption could have a material adverse effect on our business, financial condition, results of operations and cash flows.We may not be successful in establishing and maintaining strategic partnerships, which could adversely affect our ability to develop and commercialize products.A part of our strategy is to evaluate and, as deemed appropriate, enter into partnerships in the future when strategically attractive,
material adverse effect on our business.Risks Related to Commercialization of Our Product CandidatesOur future commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among physicians, patients, third-party payors and
government contracts and grants to support their research and development efforts, conducting testing and clinical trials, obtaining regulatory approvals to market products, manufacturing such
of these events could prevent us from achieving or maintaining market acceptance of our products and could substantially increase commercialization costs.Risks Related to Our IndebtednessOur level of indebtedness and debt service obligations could adversely affect our financial condition, and may make it more difficult for us to fund our operations.In September 2013 we entered into a secured credit facility pursuant to a working capital term loan facility with Ares Capital
The market price for our common stock may be influenced by many factors, including:•the success of competitive products or technologies;•results of clinical trials of our product candidates;•the timing of the release of results of our clinical trials;•results of clinical trials of our competitors' products;•regulatory actions or legal developments with respect to our products or our competitors' products;•developments or disputes concerning patent applications, issued patents or other proprietary rights;•the results of our efforts to discover, develop, acquire or in-license additional product candidates or products;•actual or anticipated fluctuations in our financial condition and operating results;•publication of research reports by securities analysts about us or our competitors or our industry;•our failure or the failure of our competitors to meet analysts' projections or guidance that we or our competitors may